HSE to fund nine delayed medicines: ‘Lessons must be learned from dysfunctional selection process’

Lessons must be learned from the “dysfunctional” drugs selection process, the Irish Pharmaceutical Healthcare Association has said.

The association, which represents the international research-based pharmaceutical industry in Ireland, welcomed confirmation from the HSE yesterday that it will fund nine delayed medicines.

After getting clarity from the Department of Health on funding, the HSE said the life-changing drugs, including those that treat cancer and heart disease, would be available later this year.